Teva appoints Canadian genetics expert to head R&D

Teva Pharmaceutical Industries Ltd. announced yesterday that Dr. Michael Hayden is joining the company as president of global R&D and chief scientific officer, based in Israel. In this new role, Dr. Michael Hayden will lead all Teva’s R&D.
Dr. Hayden is currently Killam Professor of Medical Genetics at UBC, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Director/Senior Scientist of the Centre for Molecular Medicine and Therapeutics.
He is a preeminent expert in genetics and personalized medicine and is one of the world’s leading experts on Huntington’s disease. He has extensive experience in all aspects of drug development from target identification, to all stages of clinical development through to drug submission to the various regulatory agencies around the world.

Chicago Tribune, Fri May 11 2012, Link to full text